Robin Kate Kelley
San Francisco oncologist who was lead author of KEYNOTE-966, which showed that adding pembrolizumab to gemcitabine and cisplatin helps people with advanced bile duct cancer live longer.
Overview
Robin Kate Kelley is a gastrointestinal medical oncologist at UCSF who focuses on liver and biliary cancers. She was first author of the 2023 Lancet report of KEYNOTE-966, in which pembrolizumab plus gemcitabine and cisplatin improved overall survival in advanced biliary tract cancer, and has led early trials of immunotherapy combinations in hepatocellular carcinoma, including the cabozantinib and atezolizumab study COSMIC-312.
Similar pages
not linked directly; found by shared links- PersonAndrew X. Zhu
Shares Intrahepatic cholangiocarcinoma, Hepatocellular carcinoma and the tags biliary, hcc, trialist.
- PersonJohn N. Primrose
Shares Biliary tract cancer (all types), Intrahepatic cholangiocarcinoma and the tags biliary, trialist.
- PersonGhassan K. Abou-Alfa
Shares Hepatocellular carcinoma and the tags biliary, hcc, trialist.
- PersonAngela Lamarca
Shares Biliary tract cancer (all types) and the tags biliary, trialist.
- PersonJordi Bruix
Shares Hepatocellular carcinoma and the tags hcc, trialist.
- PersonMasatoshi Kudo
Shares Hepatocellular carcinoma and the tags hcc, trialist.
- PersonAnn-Lii Cheng
Shares Hepatocellular carcinoma and the tags hcc, immunotherapy.
- PersonRichard S. Finn
Shares Hepatocellular carcinoma and the tags hcc, trialist.